Table 1.

Ongoing MSCs Cardiomyoplasty Clinical Trials^*

Project	Location	Aim	Condition	Intervention
MSC therapy in patients undergoing cardiac surgery (PROMETHEUS)	NHLBI, USA	Low and high dose intramyocardial autologous MSC injection in MI patients with chronic ischemic LVD undergoing CABG (Phase I/II)	chronic ischemic LVD	MSCs
Transendocardial autologous cells (hMSCs/hBMCs) in ischemic heart failure (TAC-HFT)	University of Miami, USA	Transendocardial delivery of autologous hMSCs and hBMCs for cardiac repair (Phase I/II)	Chronic ischemic LVD; HF	MSCs BMCs
Combination stem cell therapy for the treatment of severe CI	TCA Cellular, Therapy, USA	Intracoronary and transendocardial administration of stem cells for CI patients unsuitable for percutaneous revascularization and surgical procedures (Phase II)	Severe CI	BMNCs MSCs
MSCs to treat AMI	Orisis Therapeutics, Inc., USA	Intravenous injection of MSCs (Provacel) following AMI	AMI	MSCs
Vasculogenesis in patients with severe myocardial ischemia	Rigshospitalet, Denmark	BM MSC stimulated for endothelial differentiation for neovessel formation in ischemic tissue (Phase I/II)	Myocardial ischemia, CHD	BM MSCs
Autologous MSC therapy in HF	Rigshospitalet, Denmark	NOGA-guided direct intramyocardial injection of MSCs for cardiomyoplasty and neovessel formation in HF patients (Phase I/II)	HF	MSCs
Combined CABG and stem-cell transplantation for HF	Helsinki University, Finland	Intraoperative transmyocardial BM MSCs transplantation for low LVEF patients scheduled to CABG (Phase II)	HF	BM MSCs

^*Source: http://clinicaltrials.gov

AMI, acute myocardial infarction; CABG, coronary artery bypass graft surgery; CHD, chronic heart disease; CI, coronary ischemia; HF, heart failure; LVDf, left ventricular dysfunction; LVEF, left ventricular ejection fraction.